FC
CRSP icon

Financial Consulate’s CRISPR Therapeutics CRSP Stock Holding History

Financial Consulate’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5K Hold
105
– – ﹤0.01% 794
2025
Q4 		$5.51K Hold
105
– – ﹤0.01% 721
2025
Q3 		$6.81K Buy
+105
New +$6.03K ﹤0.01% 603

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Financial Consulate's CRSP Position: Q1 2026 in Review

Financial Consulate held its CRISPR Therapeutics (CRSP) position steady in Q1 2026 at 105 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #794.

Financial Consulate first reported a position in CRSP in Q3 2025 and has held it in 3 quarters since. The position peaked at $6.81K in Q3 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Financial Consulate held 105 shares of CRISPR Therapeutics worth $5K as of Q1 2026.
  • Financial Consulate left its CRISPR Therapeutics share count unchanged in Q1 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Financial Consulate's portfolio in Q1 2026, its #794 holding.
  • Financial Consulate first reported a position in CRISPR Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Financial Consulate's CRISPR Therapeutics position peaked at $6.81K in Q3 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Financial Consulate's 13F filing for Q1 2026, filed 21 Apr 2026.